TriSalus Life Sciences, Inc. (TLSI) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

TriSalus Life Sciences, Inc. (TLSI) Healthcare & Pipeline Overview

TriSalus Life Sciences, Inc. is a Westminster, Colorado-based immunotherapy company focused on developing and commercializing innovative treatments for liver and pancreatic tumors. It leverages proprietary pressure-enabled drug delivery technology through its TriNav and Pancreatic Retrograde Venous Infusion Systems, alongside the investigational immunotherapeutic SD-101, addressing critical unmet needs in oncology.

What Is the Investment Thesis for TLSI?

TriSalus Life Sciences, Inc. presents a research focus on addressing critical unmet needs in oncology, specifically targeting liver and pancreatic tumors with a dual approach of proprietary drug delivery systems and an investigational immunotherapeutic. The company's TriNav and Pancreatic Retrograde Venous Infusion Systems offer precise, pressure-enabled drug delivery, potentially improving efficacy for localized treatments. The development of SD-101, an immunotherapeutic targeting multiple difficult-to-treat cancers, represents a significant growth catalyst, with its success in clinical trials and subsequent regulatory approvals being key value drivers. Financially, the company operates with a high gross margin of 85.1%, indicating strong product-level profitability for its existing systems. However, a negative profit margin of -60.9% and a high debt-to-equity ratio of 269.28 highlight ongoing investment in R&D and the capital-intensive nature of biotech development. The company's market capitalization stands at $0.12 billion, with a Beta of 0.56 suggesting lower volatility relative to the broader market. Future value creation hinges on the successful advancement of SD-101 through its clinical pipeline and expanding market adoption of its specialized infusion systems.

Based on FMP financials and quantitative analysis

TLSI Key Highlights

Market Capitalization stands at $0.12 billion, reflecting its valuation as a specialized biotechnology firm focused on oncology.

• Profit Margin is -60.9%, indicating significant ongoing investment in research and development, typical for companies in the clinical-stage biotechnology sector.
• Gross Margin of 85.1% demonstrates strong profitability on its commercialized infusion systems, showcasing efficiency in product manufacturing and sales.
• Debt-to-Equity ratio is 269.28, suggesting a high reliance on debt financing for operations and development, which is common in capital-intensive industries like medical devices and drug development.
• Beta of 0.56 indicates lower volatility compared to the overall market, potentially appealing to investors seeking less market-sensitive exposure within the healthcare sector.

Who Are TLSI's Competitors?

TLSI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TLSI's Key Strengths?

Proprietary pressure-enabled drug delivery technology offers a unique approach to enhance drug penetration in solid tumors.

• Specialized infusion systems (TriNav and Pancreatic Retrograde Venous Infusion System) target difficult-to-treat liver and pancreatic cancers.
• High gross margin of 85.1% on existing commercialized products indicates strong unit economics.
• Investigational immunotherapeutic SD-101 addresses a broad range of high-unmet-need oncology indications.

What Are TLSI's Weaknesses?

Significant negative profit margin of -60.9% reflects substantial R&D expenses and ongoing operational losses.

• High debt-to-equity ratio of 269.28 indicates considerable financial leverage and potential sensitivity to market conditions.
• Reliance on the successful development and regulatory approval of investigational products like SD-101 for future growth.
• Relatively small employee base of 110 may limit the scale of commercialization and R&D efforts compared to larger competitors.

What Could Drive TLSI Stock Higher?

TLSI catalyst: Clinical trial data readouts and progress reports for SD-101 across its various indications, including hepatocellular carcinoma and pancreatic ductal adenocarcinoma, are anticipated to provide key insights into its efficacy and safety profile.

• Potential regulatory submissions and subsequent approvals for SD-101 in target markets will be critical milestones, enabling commercialization and new revenue streams.
• Continued commercialization efforts and increasing market penetration for the TriNav Infusion System are expected to drive revenue growth through broader adoption in liver tumor treatments.
• Enhanced market acceptance and utilization of the Pancreatic Retrograde Venous Infusion System will contribute to device sales, addressing the high unmet need in pancreatic cancer therapy.

What Are the Key Risks for TLSI?

Financial-distress signal — its Altman Z-Score of -3.54 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or unexpected adverse events during the development of SD-101 could significantly delay or halt its path to market, impacting future revenue projections.
• Regulatory rejections or prolonged approval processes for SD-101 or new indications for existing devices could impede market access and increase development costs.
• The company's significant negative profit margin of -60.9% indicates a high burn rate, necessitating continuous access to capital to fund ongoing research and operations.
• A high debt-to-equity ratio of 269.28 exposes the company to financial risks, including potential difficulties in securing additional financing or managing debt obligations.
• Intense competition within the oncology and medical device sectors could limit market share and pricing power for TriSalus's products and pipeline candidates.

What Are the Growth Opportunities for TLSI?

• Growth opportunity 1: The continued development and potential commercialization of SD-101 across its multiple investigational indications represents a significant growth driver. SD-101 is being evaluated for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. Each of these indications addresses a substantial patient population with high unmet needs. Successful clinical trial outcomes and subsequent regulatory approvals for even a subset of these indications could unlock significant market potential, expanding the company's revenue streams beyond its existing device sales. The global market for oncology therapeutics is projected to continue its robust growth, with immunotherapies being a key segment.
• Growth opportunity 2: Expanding the market adoption and utilization of the TriNav Infusion System for hepatic arterial infusion of liver tumors offers a clear pathway for revenue growth. Liver cancer, including primary and metastatic forms, represents a considerable global health burden. The TriNav system's pressure-enabled drug delivery technology aims to improve the efficacy of localized treatments by enhancing drug distribution within the tumor. Increased awareness, clinical evidence supporting improved patient outcomes, and broader integration into standard clinical practice by oncologists and interventional radiologists could drive higher sales volumes and market penetration for this specialized device in the coming years.
• Growth opportunity 3: The Pancreatic Retrograde Venous Infusion System, designed for pancreatic tumors, addresses one of the most aggressive and difficult-to-treat cancers. Pancreatic cancer has a notoriously poor prognosis, underscoring the urgent need for more effective therapeutic delivery methods. As clinicians seek innovative approaches to improve drug access to pancreatic tumors, the specialized nature of this infusion system could position TriSalus Life Sciences for substantial growth. Demonstrating clinical benefits and improving patient outcomes through targeted delivery could lead to increased adoption within oncology centers, contributing significantly to the company's device revenue stream over the medium to long term.
• Growth opportunity 4: Leveraging the proprietary pressure-enabled drug delivery (PEDD) technology beyond its current applications presents a compelling long-term growth opportunity. This core technology, which underpins both the infusion systems and the investigational immunotherapeutic SD-101, could potentially be adapted for other difficult-to-treat solid tumors or for the delivery of different classes of therapeutic agents. Exploring new indications or developing next-generation devices and drug combinations that utilize the PEDD platform could open up new market segments. This strategic expansion would capitalize on the company's unique technological advantage, broadening its addressable market and intellectual property portfolio.
• Growth opportunity 5: Enhancing the commercialization infrastructure and sales force for both the TriNav and Pancreatic Retrograde Venous Infusion Systems is crucial for maximizing their market potential. While the technology is innovative, effective commercialization requires robust sales, marketing, and medical education efforts to drive adoption among healthcare providers. Investing in a specialized sales team that can effectively communicate the clinical benefits and operational advantages of these systems to interventional oncologists, surgeons, and hospital administrators can accelerate market penetration. This focus on scaling commercial operations will be vital for translating technological innovation into sustained revenue growth and establishing a stronger market presence.

What Threats Does TLSI Face?

• Clinical trial failures or delays for SD-101 could severely impact future revenue and investor confidence.
• Intense competition from established pharmaceutical and medical device companies in the oncology market.
• Regulatory hurdles and lengthy approval processes for new drugs and medical devices.
• Challenges in securing adequate funding for ongoing research, development, and commercialization efforts given the capital-intensive nature of the business.

What Are TLSI's Competitive Advantages?

• Proprietary pressure-enabled drug delivery technology, which enhances the distribution and penetration of therapeutics within solid tumors.
• Specialized infusion systems, TriNav and Pancreatic Retrograde Venous Infusion System, designed for targeted delivery to liver and pancreatic tumors, addressing specific anatomical and physiological challenges.
• Focus on high-unmet-need oncology indications, particularly aggressive liver and pancreatic cancers, creating a niche market position.
• Investigational immunotherapeutic SD-101, developed with the company's unique technology, potentially offering a differentiated treatment option across multiple cancer types.

What Does TLSI Do?

TriSalus Life Sciences, Inc. is an immunotherapy company dedicated to the development and commercialization of advanced treatments for challenging liver and pancreatic tumors. Headquartered in Westminster, Colorado, the company addresses a significant unmet medical need by focusing on cancers that are historically difficult to treat effectively. At the core of its offerings are two specialized infusion systems: the TriNav Infusion System, designed for hepatic arterial infusion in the treatment of liver tumors, and the Pancreatic Retrograde Venous Infusion System, specifically engineered for the targeted delivery of therapies to pancreatic tumors. These systems are integral to the company's approach, aiming to enhance drug delivery efficiency and efficacy in localized tumor environments. Beyond its device portfolio, TriSalus Life Sciences is actively engaged in the clinical development of SD-101, an investigational immunotherapeutic. This therapeutic agent is being developed with the company's proprietary pressure-enabled drug delivery technology, which is designed to improve the distribution and penetration of drugs within solid tumors. SD-101 is currently under investigation for a broad spectrum of indications, including hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. With a team of 110 employees, TriSalus Life Sciences positions itself at the intersection of medical device innovation and immunotherapy, striving to improve outcomes for patients facing aggressive and complex cancers through targeted and enhanced therapeutic delivery.

What Products and Services Does TLSI Offer?

• Develops and commercializes immunotherapies specifically for liver and pancreatic tumors.
• Offers the TriNav Infusion System for targeted hepatic arterial infusion in liver cancer treatment.
• Provides the Pancreatic Retrograde Venous Infusion System for precise drug delivery to pancreatic tumors.
• Develops SD-101, an investigational immunotherapeutic, utilizing pressure-enabled drug delivery technology.
• Targets multiple severe cancer indications with SD-101, including hepatocellular carcinoma and various metastatic cancers.
• Focuses on improving drug distribution and penetration within solid tumors through proprietary technology.
• Aims to address significant unmet medical needs in aggressive oncology indications.

How Does TLSI Make Money?

• Generates revenue from the sales of its proprietary medical devices, specifically the TriNav Infusion System.
• Earns revenue from the sales of the Pancreatic Retrograde Venous Infusion System for pancreatic tumor treatment.
• Invests heavily in research and development for its investigational immunotherapeutic, SD-101, with future revenue potential from its commercialization upon regulatory approval.
• Leverages its pressure-enabled drug delivery technology to create differentiated products in the oncology market.

What Industry Does TLSI Operate In?

TriSalus Life Sciences operates within the highly specialized and rapidly evolving Healthcare sector, specifically positioned in the Medical - Devices industry with a strong focus on oncology. The broader market for cancer therapeutics and diagnostics is experiencing robust growth, driven by an aging global population, increasing cancer incidence, and advancements in treatment modalities like immunotherapy and targeted drug delivery. TriSalus's niche in liver and pancreatic tumors places it in an area with significant unmet medical needs, as these cancers are notoriously aggressive and challenging to treat. The competitive landscape includes large pharmaceutical companies with broad oncology portfolios, as well as smaller biotech firms developing specialized treatments and drug delivery platforms. TriSalus differentiates itself through its proprietary pressure-enabled drug delivery technology and specialized infusion systems, aiming to improve therapeutic outcomes by enhancing drug penetration and distribution within solid tumors, a key challenge in cancer therapy. This strategic positioning allows the company to capitalize on the trend towards more precise and effective cancer interventions.

Who Are TLSI's Key Customers?

• Oncologists and interventional radiologists specializing in liver and pancreatic cancer treatments.
• Hospitals and cancer treatment centers seeking advanced drug delivery solutions for solid tumors.
• Patients diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers.
• Healthcare systems looking for innovative technologies to improve patient outcomes in challenging oncology cases.

Wall Street analysts project TriSalus Life Sciences, Inc. revenue of about $52.4M for fiscal 2026, with EPS near $-0.29. The estimate reflects 3 contributing analysts.

TriSalus Life Sciences, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 83.2% below estimates on average.

TriSalus Life Sciences, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.54 places it in the distress zone, a signal of elevated financial risk.

Return on equity for TriSalus Life Sciences, Inc. stands at 273.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -45.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -8.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.35 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.6%, the inverse of the P/E and a quick read on earnings relative to price.

TriSalus Life Sciences, Inc. (TLSI) Valuation Context

Valued at $338M, TLSI is classified as a small-cap stock. Relative to its peer group, TLSI's quantitative score of 15/100 is below the peer average of 79/100.

TLSI Revenue & Earnings Trend

In Q2 2026, TLSI generated $11.4M in top-line revenue, marking a sequential increase of 28.2%. The company recorded a net loss of $9.2M, with diluted EPS of $-0.16. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, TLSI averaged $-0.32 in diluted EPS.

Company Profile

TriSalus Life Sciences, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Westminster, US. The company is led by CEO Mary T. Szela. TLSI has traded publicly since 2021.

TLSI Financials

TLSI Latest News

TLSI Analyst Consensus

TLSI MoonshotScore

Common Questions About TLSI (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources